DexCom, Inc. $DXCM Shares Sold by Cwm LLC

Cwm LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,282 shares of the medical device company’s stock after selling 2,862 shares during the period. Cwm LLC’s holdings in DexCom were worth $14,253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of DXCM. Vanguard Personalized Indexing Management LLC lifted its position in DexCom by 15.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,260 shares of the medical device company’s stock worth $3,864,000 after acquiring an additional 5,763 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in DexCom during the 2nd quarter worth approximately $372,000. Apollon Wealth Management LLC lifted its position in DexCom by 7.8% during the 2nd quarter. Apollon Wealth Management LLC now owns 21,196 shares of the medical device company’s stock worth $1,850,000 after acquiring an additional 1,526 shares in the last quarter. Fulcrum Capital LLC lifted its position in DexCom by 11.2% during the 2nd quarter. Fulcrum Capital LLC now owns 37,881 shares of the medical device company’s stock worth $3,307,000 after acquiring an additional 3,809 shares in the last quarter. Finally, DSM Capital Partners LLC lifted its position in DexCom by 252.1% during the 2nd quarter. DSM Capital Partners LLC now owns 1,435,296 shares of the medical device company’s stock worth $125,287,000 after acquiring an additional 1,027,633 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Citigroup reduced their price target on DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a research report on Wednesday, October 8th. William Blair raised DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Argus assumed coverage on DexCom in a research report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price on the stock. Finally, Barclays upped their target price on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.42.

DexCom Stock Performance

Shares of DXCM opened at $65.20 on Tuesday. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market cap of $25.57 billion, a price-to-earnings ratio of 45.28, a PEG ratio of 1.37 and a beta of 1.47. The business’s 50 day moving average is $74.20 and its two-hundred day moving average is $77.70.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $0.43 EPS. The business’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 over the last 90 days. Insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.